ima401
mAbexperimentalBi-specific
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 19, 2022 (NCT05359445)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
CD3E agonist
- Melanoma-associated antigen 3BINDING AGENT
MAGEA3 binding agent
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05359445 | Phase 1 | May 19, 2022 | Bristol-Myers Squibb, immatics Biotechnologies GmbH |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2022 |
| immatics Biotechnologies GmbH | For profit | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1